Interleukin-1α enhances the aggressive behavior of pancreatic cancer cells by regulating the α6β1-integrin and urokinase plasminogen activator receptor expression
© Sawai et al; licensee BioMed Central Ltd. 2006
Received: 09 October 2005
Accepted: 20 February 2006
Published: 20 February 2006
In human pancreatic cancer progression, the α6β1-integrin is expressed on cancer cell surface during invasion and metastasis formation. In this study, we investigated whether interleukin (IL)-1α induces the alterations of integrin subunits and urokinase plasminogen activator/urokinase plasminogen activator receptor (uPA/uPAR) expression in pancreatic cancer cells. We hypothesize that the alterations of integrin subunits and uPA/uPAR expression make an important role in signaling pathways responsible for biological behavior of pancreatic cancer cells.
IL-1α upregulated the expression of α6 and β1 integrins without any alterations of α5 and αv integrins expression. IL-1α also induced enhancement in the expression of uPA/uPAR in pancreatic cancer cells. IL-1α enhanced the proliferation, adhesion, and migration in pancreatic cancer cells, and IL-1α-induced alterations of uPA/uPAR expression correlated with the increased the migration of pancreatic cancer cells. Upregulation of α6 integrin subunit and uPA/uPAR correlated with the activation of Ras and downstream extracellular signal-regulated kinase (ERK) pathways. IL-1α-induced activation of Ras and downstream ERK can be inhibited by using inhibitory antibodies against α6 and β1 integrin and uPAR, consistent with the inhibition of proliferation, adhesion and migration of pancreatic cancer cells. Immunohistochemical analysis demonstrated a significant association between strong expressions of α6 integrin with uPAR in pancreatic cancer specimens. Furthermore, the strong expression of α6 integrin and uPAR was found to be independent prognosticator in pancreatic cancer patients.
Based on these findings, we conclude that IL-1α can induce selective upregulation of α6β1-integrin and uPA/uPAR in pancreatic cancer cells and these changes may modulate the aggressive functions of pancreatic cancer.
Pancreatic cancer is one of the most aggressive common tumors, the five-year survival rate being less than 20% despite surgery and/or chemotherapy . This very poor prognosis is mainly due to the propensity of this tumor to invade the adjacent structures and metastasize to distant organs early in the course of disease. Despite intensive efforts to improve therapy for this advanced disease, treatment remains unsatisfactory and most patients die within months as a result of rapid local spread of the tumor or metastatic dissemination. The biological characteristics underlying the aggressive behavior of these tumors are incompletely understood.
Integrins are dimeric proteins composed of noncovalently associated α and β subunits and are divided into subgroups according to their preference for binding to extracellular matrix (ECM) proteins or cell surface molecules [2–4]. These adhesion molecules play principal roles in various aspects of tumor biology. Increased expression of laminin binding integrins or decreased expression of fibronectin binding integrins has been correlated with aggressive growth and metastatic capacity of several tumors [5–8]. We previously reported that the enhancement of α6β1-integrin expression by interleukin (IL)-1α acting through IL receptor type I (IL-1RI) plays an important role in metastatic and invasive behaviors in pancreatic cancer, and proved that the strong expression of the α6 integrin subunit in pancreatic cancer tissue significantly correlated with the poor prognosis and the presence of hepatic metastases in patients with pancreatic cancer [9, 10].
The plasminogen activation cascade is one critical pathway frequently implicated in cancer cell growth, invasion, and spread [10–12]. Overexpression of urokinase plasminogen activator (uPA) and uPA receptor (uPAR) have been reported in human cancer tissues, and a strong correlation has been associated between uPA and uPAR expression levels and poor prognosis and uPA is localized in primary pancreatic cancer specimens [13, 14].
The activation of Ras and its downstream extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway is one of the important roles of integrin ligation . Furthermore, overexpression of uPAR in cancer cells is maintained by constitutively activated ERK1-dependent signaling cascade . Recently it has been demonstrated that the inhibition of the ERK/MAPK pathway suppresses the pancreatic cancer cell invasion in vitro  and colonic tumor growth in vivo . Based on these reports, integrins in association with uPAR may activate the Ras pathway to regulate proliferative and invasive behaviors of cancer cells.
The aims of this study were to identify the role of integrins and uPA/uPAR for pancreatic cancer cell adhesive and invasive capabilities and to evaluate the correlation of uPA and integrins expression with clinicopathological characteristics of pancreatic cancer patients. We demonstrated that uPA/uPAR and α6β1-integrin play important roles in enhancement of adhesive and invasive capabilities of pancreatic cancer cells through Ras/ERK signaling pathway. Furthermore, immunohistochemical analysis demonstrated that strong expression of uPAR and α6 integrin was found to be independent prognostic indicator of pancreatic cancer patients. Our results suggest that IL-1α induces discernibly aggressive capability in pancreatic cancer and that these regulations can be helpful to understand biological processes for better translational treatment for pancreatic cancer patients.
Integrins, IL-1RI, uPA and uPAR expression and alteration in pancreatic cancer cells
Alteration of integrin subunits and uPAR in pancreatic cancer cells in response to IL-1α
Mean fluorescence intensity
310 ± 18
350 ± 12
411 ± 14
383 ± 34a
344 ± 18
399 ± 16
40 ± 6
72 ± 9
60 ± 8
44 ± 4
68 ± 8
61 ± 6
520 ± 21
230 ± 11
441 ± 18
833 ± 44a
344 ± 27a
612 ± 32a
77 ± 8
61 ± 9
51 ± 8
71 ± 7
65 ± 9
58 ± 6
997 ± 42
814 ± 31
810 ± 33
1229 ± 41a
1183 ± 22a
1322 ± 24a
34 ± 3
42 ± 2
51 ± 5
143 ± 10a
166 ± 13a
191 ± 9a
219 ± 17
299 ± 31
291 ± 18
423 ± 26a
588 ± 21a
524 ± 19a
Proliferation of pancreatic cancer cells in response to IL-1α
Adhesion of pancreatic cancer cells in response to IL-1α
Migration of pancreatic cancer cells in response to IL-1α
Migration of pancreatic cancer cells enhanced by IL-1α and its suppresion by anti-integrin, anti-uPAR antibodies
Pancreatic cancer cells (number of migrated cells)
32.0 ± 6.24
27.7 ± 3.09
33.3 ± 3.09
59.2 ± 6.65 a
47.0 ± 7.13 a
63.2 ± 7.13 a
IL-1α + IgG
58.3 ± 8.69 a
45.8 ± 6.82 a
62.5 ± 6.82 a
21.0 ± 1.35 a
19.9 ± 2.21 a
23.6 ± 2.48 a
IL-1α + anti-α6 integrin
23.0 ± 2.45 a
22.3 ± 3.34 a
23.3 ± 3.34 a
21.1 ± 1.35 a
23.3 ± 1.41 a
22.1 ± 2.14 a
IL-1α + anti-β1 integrin
23.7 ± 2.05 a
22.5 ± 2.75 a
23.7 ± 2.75 a
25.2 ± 2.31 a
20.1 ± 2.07 a
24.1 ± 1.18 a
IL-1α + anti-uPAR
24.5 ± 4.28 a
21.2 ± 2.48 a
24.8 ± 2.48 a
IL-1α activates Ras and downstream ERK pathway in pancreatic cancer cells
Immunohistochemical localization of α6 and β1 integrin and uPAR in ductal adenocarcinoma of pancreas
Comparison of α6 integrin and uPAR expression and clinicopathological findings
Strong co-expression both of α6 integrin and uPAR
Yes (n = 16)
No (n = 26)
64.4 ± 8.6
64.3 ± 9.5
Lymph node matastasis
Cancer cell differentiation
Intrapancreatic nerve invasion
Lymphatic system invasion
Venous system invasion
Immunohistochemical evaluation of α6 integrin and uPAR expression in pancreatic tissues
Multiple analysis on prognosis of patients with pancreatic cancer
95% confidence interval
Cancer cell differentiation
0.669 – 3.526
0.528 – 1.853
Intrapancreatic nerve invasion
0.605 – 1.890
Lymphatic system invasion
0.702 – 3.476
Venous system invasion
0.325 – 1.308
Lymph node metastasis
0.404 – 1.207
Strong expression of α6 integrin
0.295 – 0.782
Strong expression of uPAR
0.276 – 0.819
In this study, we demonstrate that IL-1α-induced proliferation, adhesion and migration of pancreatic cancer cells correlated with activation of Ras and downstream ERK pathway. Inhibition of α6, β1 integrin, or uPAR signaling pathway inhibited IL-1α-induced activation of Ras/ERK pathway with subsequent inhibition in proliferation, adhesion and migration of pancreatic cancer cells. These observations suggest that α6β1-integrin and uPAR play a significant role in IL-1α-regulated functions of pancreatic cancer cells.
Enhancement of α6 integrin expression has been reported previously for cells undergoing malignant transformation such as fibroblasts , squamous cell carcinoma , hepatocytes , mouse epidermal keratinocytes , malignant melanoma , prostate cancer , and pancreatic cancer [8, 9]. We previously reported that the expression of only two subunits, the α6 and β1 integrin subunits, by the high-metastatic cancer cell lines was enhanced by IL-1α, and the adhesive and invasive capability was also enhanced by IL-α. In this study, we have determined the enhancement of α6β1-integrin expression by IL-1α and the subsequent increased migration of pancreatic cancer cell lines which express IL-1RI protein to Matrigel, which contains several ECM proteins. The α6 integrin subunit is a major laminin receptor for adhesion in laminin-rich basement membranes. In regard to the expression of α3 integrin which binds to collagen type I, fibronectin, and laminin with low specificity, we could not detect any changes in Capan-2 and SW1990 cell lines, whereas its expression was significantly enhanced in BxPC-3 cell lines. The enhancement of α5 and αv integrins expression was not observed in response to IL-1α in this study. Although the relative contributions of these adhesion molecules alterations appear to vary depending on the cell line and the stimulus used, in this study we can suggest that the α6 integrin subunit which has a strong adhesion affinity to laminin is one of the most important biological molecules for cancer cell adhesion and migration.
The strong expression of α6 integrin was observed in 48% of cancerous regions of the pancreas, while the α6 integrin subunit was weakly expressed in non-cancerous regions (p < 0.01). Interestingly, in non-cancerous regions of pancreatic tissues, α6 integrin subunit was not or only weakly expressed. The α6 integrin subunit is an integral part of hemidesmosomes. It is possible that the detachment of cancer cells from the pancreatic tissues and resultant metastasis formation in the target organs may be easier where α6 integrin subunit expression in non-cancerous regions of pancreatic tissues is weak or not observed. And the enhanced expression of the α6 integrin subunit via IL-1 signaling transmitted through IL-1RI may results in increased invasive and metastatic capabilities of cancer cells in cancerous tissues. In addition, the induction of microenvironment induced expression of adhesion and metastasis-related molecules may serve to regulate the process of pancreatic cancer proliferation, adhesion and invasion.
In this study, no expression of β4 integrin subunit was observed in three pancreatic cancer cell lines studied. The lack of β4 integrin subunit is consistent with the reported for prostate cancer. The progression of the cancer from intraepithelial neoplasia to invasive prostate carcinoma results in loss of β4 integrin expression and is replaced by alternative α6β1-integrin functions . Concerning the β integrin subunit, pancreatic cancer cells that express β1 integrin with naturally acquired high constitutive activity were able to maintain the necessary balance of adhesion and release by means of coordinated activation and inactivation of integrin affinity .
In this study, we have focused in identifying some of the molecules that are regulated by IL-1α with a view to gain better understanding of the IL-1α induced molecular mechanisms that may contribute to the progression and dissemination of pancreatic cancer. We previously reported that blocking IL-1RI with neutralizing antibody inhibited the adhesion and migration of pancreatic cancer cells. We also proved that IL-1α had no demonstrable effect on pancreatic cancer cell lines without expressing IL-1RI . We herein demonstrated that the proliferation of pancreatic cancer cells was enhanced by exposing to IL-1α. IL-1α also enhanced the adhesion and migration of pancreatic cancer cell lines expressing the IL-1RI, and these enhancements correlated with the enhancement of α6β1-integrin and uPA/uPAR expression. Based on our results, enhancement of α6β1-integrin and uPA/uPAR expression in pancreatic cancer cells occurs in the presence of IL-1RI.
The concomitant overexpression of uPA and uPAR was found to be associated with shorter survival in pancreatic cancer patients . On the other hand, Harvey et al. reported that there were not any correlation with the co-expression of uPA and uPAR . In our immunohistochemical analysis, uPAR was strongly expressed in 59.5% of cancerous regions of pancreatic cancer, whilst the expression of uPAR was absent in non-cancerous region of the pancreas. A significant association was demonstrated between strong expression of α6 integrin subunit and uPAR in pancreatic cancer specimens. The strong co-expression of α6 integrin subunit with uPAR supports our results in vitro and suggests that α6β1-integrin and uPAR play a significant role in aggressive functions of pancreatic cancer cells. In this study, we demonstrated a significant correlation between co-expression of α6 integrin subunit with uPAR and the presence of liver metastasis, lymph node metastasis, and the retroperitoneal invasion in patients with pancreatic ductal adenocarcinoma. We also found that the strong expression of α6 integrin subunit and uPAR correlated with the patient's poor prognosis. Furthermore, multivariate analysis demonstrated that the strong expression of α6 integrin subunit and uPAR can be independent prognostic indicators in patients with pancreatic ductal adenocarcinoma. These observations suggest that the diagnostic evaluation of α6 integrin subunit and uPAR expression might provide valuable prognostic information to aid treatment strategies for pancreatic cancer patients.
Recent reports demonstrated that integrins directly associate with uPAR to mediate cellular function [29–32]. uPAR has been reported to associate with many signaling molecules and to mediate signal transduction . The α6 integrin/uPAR interaction has been demonstrated in human ovarian cancer cell  and prostate cancer cell lines , and these data suggest that signaling through α6 integrin and uPAR may be essential for ensuring cancer phenotype expression. Recently, Ahmed et al. reported the loss of uPA/uPAR-mediated ERK activation with downregulation of uPAR expression in colon cancer cells . They also reported that the upregulation of α6 integrin and uPA/uPAR correlated with the activation of Ras and its downstream ERK pathway in ovarian cancer cells . uPA/uPAR interaction with β1 integrin has been shown to activate ERK pathway  and disruption oft his interaction can result in loss of adhesion and tumor progression in nude mice . Furthermore, it has been reported that integrin-ECM interactions activate ERK 1/2 signaling cascades . We demonstrated that IL-1α stimulation and cancer cell adhesion to collagen type IV enhanced the focal adhesion kinase (FAK) protein association with β1 integrin and FAK phosphorylation. And these enhancements correlated with the activation of Ras/ERK signaling pathways in pancreatic cancer cells . The integrin-uPAR interaction is very important as many integrin receptors activate intracellular signal pathways to fully activate cell survival and proliferation pathways .
In summary, upregulation of α6 integrin subunit and uPA/uPAR correlated with the activation of Ras and downstream ERK pathways. IL-1α-induced activation of Ras and downstream ERK pathway can be inhibited by using inhibitory antibodies against α6 and β1 integrin and uPAR, consistent with the inhibition of proliferation, adhesion and migration of pancreatic cancer cells. Immunohistochemical analysis demonstrated a significant association between strong co-expression of α6 integrin and uPAR in pancreatic cancerous regions, and the strong expression of α6 integrin and uPAR was found to be independent prognostic indicators in pancreatic cancer patients. Based on these results, IL-1α induces discernibly aggressive capability in pancreatic cancer and these regulations can be helpful to understand biological processes of pancreatic cancer.
The human pancreatic cancer cell lines, BxPC-3, Capan-2, and SW1990, were from the American Type Culture Collection (Rockville, MD). The BxPC-3 cells were maintained in RPMI 1640 (Gibco BRL, Eggenstein, Germany) supplemented with 10% fetal calf serum (FCS). SW1990 and Capan-2 cells were maintained in Dulbecco modified Eagle medium (Gibco BRL) with high glucose and 10% FCS. All cells were incubated at 37°C in a humidified atmosphere of 5% CO2 in air.
Human pancreatic tissues were obtained in Department of Gastroenterological Surgery, Nagoya City University Hospital with patients' or their relatives' informed consent. Tissue samples were fixed in 10% formalin and then embedded in paraffin. Immunohistochemical studies on tumor-free pancreatic tissue were performed using non-cancerous regions of tumor-containing pancreas.
Recombinant human IL-1α (rIL-1α) was provided by Gibco BRL. The monoclonal antibodies (mAbs) used included anti-β1 (P5D2), anti-α6 (GoH3), anti-αv (AV1), and anti-β4 (439-9B) from Chemicon International, Inc. (Temecula, CA, USA); anti-IL-1RI (35730) from Genzyme/Techne; anti-uPA-specific antibody (#3471) and uPAR specific antibody (#3936) from American Diagnostica (Temecula, CA, USA); anti-phospho-ERK 1/2 (Thr 202/Tyr 204), anti-ERK 1 (C-16), and anti-ERK 2 (C-14) from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Western blot analysis
The cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1% Triton X-100, 0.1% SDS, 0.1% Nonidet P-40, 2 mM PMSF, 1 mM vanadate, 5 μg/ml Trasylol, 10 μM Pepstatin A and 10 μM leupeptin). Following a low-speed spin (500 rpm, 5 min) to pellet nuclei and cell debris, the supernatant fraction was further centrifuged (100,000 g, 30 min), and the crude plasma membranes obtained in the pellet were re-suspended in 20 mM Tris-HCl (pH 7.4). Protein concentrations were determined with a BCA protein assay kit (Pierce, Rockford, IL, USA). The amounts of samples were 50 μg per each lane. Western blot analyses were performed following SDS-PAGE. The lysates were separated by 10% SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (Immobilon PVDF; Nihon Millipore Ltd., Tokyo, Japan) and immunoblotted with each antibody.
Flow cytometric analyses
Flow-cytometric analysis was performed using FACScan (Becton Dickinson Immunocytometry Systems, Mountain View, CA, USA). The indirect immunofluorescence method was applied to stain the cancer cells with various monoclonal antibodies as the primary antibody (stained for 30 min at room temperature), followed by the addition of the secondary antibody conjugated fluorescein isothiocyanate (Dako, Glostrup, Denmark). Results are expressed as mean fluorescence intensity for triplicate determinations.
Cell proliferation assay
Pancreatic cancer cell proliferation was determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction method] assay and cell count. In MTT assay, pancreatic cancer cells were seeded at a density of 2 × 103 cells/100 μl into 96-well plates and allowed to adhere overnight. Culture media were replaced, and the cells then cultured in medium alone (control) or in medium with/without 10 ng/ml of rIL-1α. After 24 h of incubation, cells were cultured for 4 h with the metabolic substrate tetrazolium salt MTT at a final concentration of 0.5 mg/ml. Formazan was detected spectorphotometically at 540 nm with a multiwell spectrophotometer (ELISA Reader; Biotek Instruments, Burlington, VT, USA).
In cell count, pancreatic cancer cells were seeded at a density of 2 × 105 cells on 35 mm well in media containing 10% FCS. After 24 h, cells were starved with 0.5% FCS for another 24 hours. Culture media was replaced to the fresh serum free media, and added rIL-1α at concentration of 10 ng/ml. After 24 h incubation, cells were washed once with phosphate-buffered saline (PBS), trypsinized, and centrifuged for 3 min at 1,500 rpm. The cell pellet was re-suspended in 2 ml of PBS and cells were counted using a light microscope.
Before the stimulating experiments with IL-1α were attempted, the lowest effective concentration was determined using rIL-1α at concentrations of 0.1 ng/ml, 0.5 ng/ml, 1.0 ng/ml, 10 ng/ml, and 100 ng/ml. A concentration of 10 ng/ml was determined to be the lowest effective concentration for stimulating experiments (data not shown). In some experiments, 0.5 μg/ml anti-α6 integrin or anti-β1 integrin mAbs was added to the cancer cells for 24 h. Before the blocking experiments were attempted, the lowest effective antibody concentration was determined using antibodies at concentrations of 0.1 μg/ml, 0.25 μg/ml, 0.5 μg/ml, 0.75 μg/ml, and 1.0 μg/ml. A concentration of 0.5 μg/ml was determined to be the lowest effective concentration for blocking experiments (data not shown). Experiments were performed in triplicate and repeated three times.
Adhesion assay was performed as described previously with some modifications . 24-well plates coated with laminin, the putative ligand of the α6β1-integrin, were obtained from Becton-Dickinson Labware (Franklin Lakes, NJ, USA). Briefly, cancer cells were incubated for 24 hours with/without rIL-1α (10 ng/ml) and then added (2 × 105 cells/well) to each well and incubated at 37°C for 30 min. The wells were then washed three times with PBS to remove unattached cells. In some experiments, 0.5 μg/ml anti-α6 or anti-β1 integrin antibodies were added to the cancer cells for >30 min prior to addition of rIL-1α.
The migration response of pancreatic cancer cells in response to IL-1α was determined by using Matrigel-coated invasion chambers (Becton and Dickinson, USA). Cancer cells were added (1 × 105 cells/well) to the inner chamber of a cell culture insert and incubated at 37°C for 24 h, either with culture media containing 10 ng/ml rIL-1α or with culture media containing 10 ng/ml rIL-1α and 0.5 μg/ml anti-α6 integrin, anti-β1 integrin, or anti-uPAR antibodies. Complete medium containing 20% fetal bovine serum served as a chemo-attractant in the lower chamber. To quantitate migration, the filters were fixed in 70 % ethanol for 30 min and stained with Giemsa. Cells were removed from the upper surface of the filters by rubbing gently with a cotton-tipped applicator. Cells that had migrated through the membrane were counted in five random microscope fields of the lower filter surface.
Ras activation assay
The activation state of Ras was determined using the Ras Activation Assay Kit provided by Upstate (Lake Placid, NY, USA). Briefly, pancreatic cancer cells were serum starved for 24 h, and then incubated in serum-free medium with/without rIL-1α (10 ng/ml) for 30 min. Cells were harvested and lysed in lysis buffer (100 mM HEPES, pH 7.5, 200 mM NaCl, 1% Nonidet P-40, 10 mM MgCl2, 5 mM EDTA and 10% glycerol), and supernatant prepared by centrifugation for 5 min at 4°C at 14,000 g. Ras-GTP from various treated lysates was "pulled down" using the GST fusion protein corresponding to human Ras binding domain of Raf-1 bound to agarose. The presence of Ras-GTP was detected by Western blotting using anti-Ras antibody (Upstate).
Pancreatic tissues were studied using the labeled streptavidin biotin method [40, 41]. Specimens were sectioned at 3.5-μm thick and deparaffinized. After rinsing in phosphate-buffered saline (pH 7.2), 10% bovine serum (Wako, Osaka, Japan) was applied for 10 min to block nonspecific binding. Sections were then incubated with anti-α6 integrin (overnight at 4°C), anti-β1 integrin (over night at 4°C), or anti-uPAR (60 min at 37°C) mAbs as primary antibodies. After rinsing in phosphate-buffered saline, sections were treated with biotinylated anti-mouse immunoglobulin (Ig) (Dako, Copenhagen, Denmark) for 10 min. After rinsing in phosphate-buffered saline, sections were treated with horseradish peroxidase-labeled streptavidin (Dako, Copenhagen, Denmark) for 10 minutes. The peroxidase reaction was visualized by incubating the sections with 0.02 % 3,3'-diaminobenzidine tetrahydrochloride in 0.05 M Tris buffer (pH 7.6) with 0.01 % hydrogen peroxide, followed by hematoxylin counterstaining. Negative control sections were prepared using normal mouse IgG instead of primary antibody.
Two observers (H.S. and H.F.) independently evaluated the immunostaining results. The concordance ratio was > 90%. Differences of opinion were resolved by reaching a consensus with the assistance of a third evaluator (Y.M.). The intensity of tissue staining was graded semiquantitatively on a 4-point scale (-, +, ++, and +++). Likewise, the proportion of cells stained was assessed on a 4-point scale (1, 0–15%; 2, 15–50%; 3, 50–85%; 4, 85–100% cells stained). To evaluate immunohistochemical findings from pancreatic cancer tissues, cases were classed in strongly staining (Group S) and weakly staining groups (Group W) by intensity and proportion of immunostaining. Immunostaining of intensity more than +++ or a staining area was more than 3 for α6 integrin subunit, β1 integrin subunit, or uPAR was defined as Group S.
Statistical comparisons were made using the Student's t test for paired observations or by one-way ANOVA for multiple comparisons. The Mann-Whitney U test was used to compare the immunohistochemical characteristics. Differences between Kaplan-Meier survival curves based on Immunohistochemical analysis were tested with the Wilcoxon test. Multiple survival analysis was calculated according to Cox's proportional hazards model. Statistical significance was indicated by p < 0.05. Data are presented as mean ± standard deviations (s.d.). Each experiment was repeated three times and was carried out in triplicate.
urokinase plasminogen activator
urokinase plasminogen activator receptor
extracellular signal-regulated kinase
IL-1 receptor type I
mitogen activated protein kinase
focal adhesion kinase
fetal calf serum
SDS-polyacrylamide gel electrophoresis
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction method
The authors thank M. Miyake for skilful technical assistance in immunohistochemistry.
- Li D, Xie K, Wolff R, Abruzzese JL: Pancreatic cancer. Lancet. 2004, 363: 1049-1057. 10.1016/S0140-6736(04)15841-8.View ArticlePubMed
- Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992, 69: 11-25. 10.1016/0092-8674(92)90115-S.View ArticlePubMed
- Aguiar CB, Lobao-Soares B, Alvarez-Silva M, Trentin AG: Glycosaminoglycans modulate C6 glioma cell adhesion to extracellular matrix components and alter cell proliferation and cell migration. BMC Cell Biol. 2005, 6: 31-10.1186/1471-2121-6-31.View ArticlePubMed
- Rahman S, Patel Y, Murray J, Patel KV, Sumathipala R, Sobel M, Wijelath ES: Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. BMC Cell Biol. 2005, 6: 8-10.1186/1471-2121-6-8.PubMed CentralView ArticlePubMed
- Sugiyama M, Speight PM, Prime SS, Watt FM: Comparison of integrin expression and terminal differentiation capacity in cell lines derived from oral squamous cell carcinomas. Carcinogenesis. 1993, 14: 2171-2176.View ArticlePubMed
- Shaw LM, Chao C, Wewer UM, Mercurio AM: Function of the integrin alpha 6 beta 1 in metastatic breast carcinoma cells assessed by expression of a dominant-negative receptor. Cancer Res. 1996, 56: 959-963.PubMed
- Vogelmann R, Kreuser ED, Adler G, Lutz MP: Integrin α6β1 role in metastatic behavior of human pancreatic carcinoma cells. Int J Cancer. 1999, 80: 791-795. 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4.View ArticlePubMed
- Sawai H, Funahashi H, Yamamoto M, Okada Y, Hayakawa T, Tanaka M, Takeyama H, Manabe T: Interleukin-1α enhances integrin α6β1 expression and metastatic capability of human pancreatic cancer. Oncology. 2003, 65: 167-173. 10.1159/000072343.View ArticlePubMed
- Sawai H, Funahashi H, Matsuo Y, Yamamoto M, Okada Y, Hayakawa T, Manabe T: Expression and prognostic roles of integrins and interleukin-1 receptor type I in patients with ductal adenocarcinoma of the pancreas. Dig Dis Sci. 2003, 48: 1241-1250. 10.1023/A:1024276821731.View ArticlePubMed
- Blasi F: Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost. 1999, 82: 298-304.PubMed
- Khatib AM, Nip J, Fallavollita L, Lehmann M, Jensen G, Brodt P: Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor αvβ3. Int J Cancer. 2001, 91: 300-308. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1055>3.3.CO;2-E.View ArticlePubMed
- Lee KH, Bae SH, Lee JL, Hyun MS, Kim SH, Song SK, Kim HS: Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer. Oncology. 2004, 66: 210-217. 10.1159/000077997.View ArticlePubMed
- Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, Korc M, Buchler MW: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer. 1997, 75: 388-395.PubMed CentralView ArticlePubMed
- Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, Smith RC: Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction. J Gastroenterol Hepatol. 2005, 20: 256-263. 10.1111/j.1440-1746.2004.03531.x.View ArticlePubMed
- Clark EA, Brugge JS: Integrins and signal transduction pathways: the road taken. Science. 1995, 268: 233-239.View ArticlePubMed
- Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D: Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene. 1997, 14: 2563-2573. 10.1038/sj.onc.1201098.View ArticlePubMed
- Okada Y, Eibl G, Guha S, Duffy JP, Reber HA, Hines OJ: Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin Exp Metastasis. 2004, 21: 285-292. 10.1023/B:CLIN.0000046131.24625.54.View ArticlePubMed
- Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1995, 5: 810-816. 10.1038/10533.View Article
- Sobin LH, Wittekind Ch: UICC TNM Classification of Malignant Tumors. 2002, Indianapolis, IN: John Wiley & Sons, 6
- Lin CS, Zhang K, Kramer R: Alpha 6 integrin is up-regulated in step increments accompanying neoplastic transformation and tumorigenic conversion of human fibroblasts. Cancer Res. 1993, 53: 2950-2953.PubMed
- Van Waes C, Surh DM, Chen Z, Kirby M, Rhim JS, Brager R, Sessions RB, Poore J, Wolf GT, Carey TE: Increase in suprabasilar integrin adhesion molecule expression in human epidermal neoplasms accompanies increased proliferation occurring with immortalization and tumor progression. Cancer Res. 1995, 55: 5434-5444.PubMed
- Begum NA, Mori M, Matsumata T, Takenaka K, Sugimachi K, Barnard GF: Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology. 1995, 22: 1447-1455. 10.1016/0270-9139(95)90151-5.View ArticlePubMed
- Gomez M, Navarro P, Quintanilla M, Cano A: Expression of alpha 6 beta 4 integrin increases during malignant conversion of mouse epidermal keratinocytes: association of beta 4 subunit to the cytokeratin fraction. Exp Cell Res. 1992, 201: 250-261. 10.1016/0014-4827(92)90272-A.View ArticlePubMed
- Danen EH, van Muijen GN, van de Wiel-van Kemenade E, Jansen KF, Ruiter DJ, Figdor CG: Regulation of integrin-mediated adhesion to laminin and collagen in human melanocytes and in non-metastatic and highly metastatic human melanoma cells. Int J Cancer. 1993, 54: 315-321.View ArticlePubMed
- Rabinovitz I, Nagle RB, Cress AE: Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis. 1995, 13: 481-491. 10.1007/BF00118187.PubMed CentralView ArticlePubMed
- Demetriou MC, Cress AE: Integrin clipping: A novel adhesion switch?. J Cell Biochem. 2004, 91: 26-35. 10.1002/jcb.10675.PubMed CentralView ArticlePubMed
- Arao S, Masumoto A, Otsuki M: β1 integrins play an essential role in adhesion and invasion of pancreatic carcinoma cells. Pancreas. 2000, 20: 129-137. 10.1097/00006676-200003000-00004.View ArticlePubMed
- Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SN, Driscoll DL, Gibbs JF: Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res. 2003, 9: 4935-4943.PubMed
- Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA: A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999, 144: 1285-1294. 10.1083/jcb.144.6.1285.PubMed CentralView ArticlePubMed
- Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok S, Baker MS: Overexpression of alphavbeta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis. 2002, 23: 237-244. 10.1093/carcin/23.2.237.View ArticlePubMed
- Artym VV, Kindzelskii AL, Chen WT, Petty HR: Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. Carcinogenesis. 2002, 23: 1593-1601. 10.1093/carcin/23.10.1593.View ArticlePubMed
- Ahmed N, Riley C, Oliva K, Rice G, Quinn M: Ascites induces modulation of α6β1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer. 2005, 92: 1475-1485. 10.1038/sj.bjc.6602495.PubMed CentralView ArticlePubMed
- Aguirre-Ghiso JA, Kovalski K, Ossowski L: Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999, 147: 89-104. 10.1083/jcb.147.1.89.View ArticlePubMed
- Demetriou MC, Pennington ME, Nagle RB, Cress AE: Extracellular alpha 6 integrin cleavage by urokinase-type plasminogen activator in human prostate cancer. Exp Cell Res. 2004, 94: 550-558. 10.1016/j.yexcr.2003.11.023.View Article
- Ahmed N, Oliva K, Wang Y, Quinn M, Rice G: Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br J Cancer. 2003, 89: 374-384. 10.1038/sj.bjc.6601098.PubMed CentralView ArticlePubMed
- van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, Quax P, Karperien M, Papapoulos S, Lowik C: Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol. 2001, 159: 971-982.PubMed CentralView ArticlePubMed
- Crowe DL, Ohannessian A: Recruitment of focal adhesion kinase and paxillin to β1 integrin promotes cancer cell migration via mitogen activated protein kinase activation. BMC Cancer. 2004, 4: 18-10.1186/1471-2407-4-18.PubMed CentralView ArticlePubMed
- Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T: Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol Cancer. 2005, 4: 37-10.1186/1476-4598-4-37.PubMed CentralView ArticlePubMed
- Miyamoto S, Teramoto H, Gutkind JS, Yamada KM: Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol. 1996, 135: 1633-1642. 10.1083/jcb.135.6.1633.View ArticlePubMed
- Jean LG, Therese T, Stratis A: The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem. 1979, 27: 1131-1139.View Article
- Gary SW, Roger W: Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. J Histochem Cytochem. 1981, 29: 1196-1204.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.